The concern of generic competition has consistently loomed above copyright’s famous drug, Sildenafil, sparking questions about the future of related drug portfolios. While initial times saw significant profits, the patent expiration has opened the way for discounted alternatives, likely lowering revenue and presenting a real danger for investors